A Randomized, Multicenter, Open-Label, Phase 3 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor PCI-32765 (Ibrutinib) Versus Rituximab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Trial Profile

A Randomized, Multicenter, Open-Label, Phase 3 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor PCI-32765 (Ibrutinib) Versus Rituximab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 13 Apr 2017

At a glance

  • Drugs Ibrutinib (Primary) ; Rituximab
  • Indications Chronic lymphocytic leukaemia; Lymphoma
  • Focus Registrational; Therapeutic Use
  • Acronyms BRILLIANCE
  • Sponsors Janssen; Janssen Research & Development
  • Most Recent Events

    • 05 Jan 2017 Planned End Date changed from 1 Feb 2017 to 1 Jun 2017.
    • 22 Jan 2016 Status changed from recruiting to active, no longer recruiting, as reported by ClinicalTrials.gov.
    • 22 Sep 2015 Planned primary completion date changed from 1 Aug 2015 to 1 May 2016, as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top